The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510700, PR China.
State Key Laboratory of Chemical Biology and Drug Discovery, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong, China.
Eur J Med Chem. 2019 Jan 1;161:141-153. doi: 10.1016/j.ejmech.2018.10.039. Epub 2018 Oct 17.
The increasing incidences of multidrug resistant bacterial infections urge the development of novel antibacterial having a new mechanism of action. The small molecule-based inhibitors targeting at the cell division protein FtsZ has been recognized as a promising approach to search for new antibacterial with high potency. In the present study, a series of novel 2,4-disubstituted-6-thiophenyl-pyrimidine derivatives were synthesized and their antibacterial activities against clinically related pathogens were investigated. The compounds show strong antibacterial activities against MRSA and VREs. The antibacterial activity of compound Bb2 against MRSA and VREs (MIC values: 2 μg/mL) is stronger than that of methicillin and vancomycin. From the in vitro and in vivo results, Bb2 was found to inhibit GTPase activity and FtsZ polymerization. The compound is able to inhibit bacterial cell division through interacting with GTP binding site of FtsZ and thus causing cell death. In addition, S. aureus was found to develop resistance to methicillin but not for Bb2, which was proved in our resistance generation experiments.
越来越多的多重耐药菌感染促使人们开发具有新作用机制的新型抗菌药物。针对细胞分裂蛋白 FtsZ 的小分子抑制剂已被认为是寻找具有高潜力的新型抗菌药物的有前途的方法。在本研究中,合成了一系列新型 2,4-二取代-6-噻吩嘧啶衍生物,并研究了它们对临床相关病原体的抗菌活性。这些化合物对 MRSA 和 VREs 具有很强的抗菌活性。化合物 Bb2 对 MRSA 和 VREs 的抗菌活性(MIC 值:2μg/mL)强于甲氧西林和万古霉素。从体外和体内结果来看,Bb2 被发现抑制 GTPase 活性和 FtsZ 聚合。该化合物能够通过与 FtsZ 的 GTP 结合位点相互作用抑制细菌细胞分裂,从而导致细胞死亡。此外,我们的耐药性产生实验证实,金黄色葡萄球菌对甲氧西林产生耐药性,但对 Bb2 没有耐药性。